GNBT - Generex Biotechnology's COVID-19 Vaccine Could Outperform Competition
Below I will briefly touch on leading COVID-19 vaccine competitors, before diving into common issues each of these leading vaccine products have.
Fortunately, a COVID-19 vaccine from NuGenerex Immuno-Oncology, AKA NGIO, a subsidiary of thinly-traded Generex Biotechnology (GNBT), will likely avoid the critical issues leading COVID-19 vaccines in development are burdened with. Generex is gaining recognition in the vaccine industry with its proprietary vaccine platform, "Ii-Key." Generex also appears significantly undervalued based on its new management paired with a recent COVID-19 partnership targeting Malaysia and another agreement for China.
In the recent coronavirus